InvestorsHub Logo
Followers 25
Posts 570
Boards Moderated 0
Alias Born 06/11/2011

Re: pgsd post# 445245

Sunday, 02/20/2022 4:13:00 AM

Sunday, February 20, 2022 4:13:00 AM

Post# of 716347
A question.
In the linked article in "Frontiersin.org", the therapy immediately following DCVax-L (ref. 83) was using an agent called "Audencel" (ref. 84). This was also an autologous dendritic cell vaccine primed with lysed GBM tissue but it failed. It's failure was reported in Cancers (Basel) (2018) 10:372–86. doi: 10.3390/cancers10100372, but I cannot access the full artcle, only the abstract.
Can anybody tell me what differences there were in the production of the failed treatment, "Audencel", and the production of DCVax-L?

Many thanks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News